Aligning U.S. With EU Cosmetic Definition Could Enable Claims, Reduce FDA Warnings
This article was originally published in The Rose Sheet
Executive Summary
Under the European Cosmetics Regulation, cosmetics by definition can “protect” parts of the body and “keep them in good condition,” which provides latitude for structure/function claims that firms do not have in the U.S. While there is interest, particularly among multinationals, for similar license in the states, the tradeoff could be more burdensome requirements for efficacy and safety substantiation that smaller companies could not support.
You may also be interested in...
Pollution Protection, Blue Light Defense Among Cosmetic Tests In High Demand
Craig Weiss, president of Consumer Product Testing Company, discussed trending cosmetics claims and testing that can be used to support them, as well as “claims that perhaps should not be made,” at ICMAD’s regulatory workshop in May.
ASA: Olay Regenerist 'Cell By Cell' Exfoliation Claims Imply 'Physiological' Effects
Ads claiming P&G's Olay Regenerist skin-care line “re-energizes skin’s appearance cell by cell” mislead consumers into expecting deeper cellular changes rather than mere surface exfoliation, an implied benefit unsupported by the firm's evidence, according to the UK’s independent regulator.
FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims
FDA cites Reviva for unapproved drug claims on eight of its products marketed as cosmetics. Included among targeted claims are familiar statements about collagen production, inflammation reduction and other benefits the agency views as structure/function effects. A number of the claims onceivably could be allowed under the revised "cosmetic" definition proposed by the Cosmetic Modernization Amendments of 2015.